Key facts
- This page summarizes Ramona Doyle's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2022, 19:19.
Ramona Doyle - 16 May 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- RXRX
- Reported as of
- 16 May 2022
- Net transaction value
- -$4,717
- SEC form
- 4
- Accepted by SEC
- 18 May 2022, 19:19:17 UTC
- Prior SEC filing
- 04 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Golightly, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ramona Doyle filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 18 May 2022.
Change
- Previous filing in this sequence was filed on 04 Apr 2022.
- Current net transaction value: -$4,717.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Tax liability
- Transaction value
- $4,717
- Shares
- -832
- Change %
- -0.68%
- Price
- $5.67
- Shares after
- 121,110
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.